The prevalence of diabetes was similar across people who were HIV-infected antiretroviral therapy (ART)-naïve, on ART and participants from a community based prevalence survey.

Impaired glucose tolerance (IGT) and impaired fasting glycaemia (IFG) were differentially prevalent by HIV status and treatment regimen.

Participants on lopinavir/ritonavir-based regimens were four-times and almost two-times more likely to have dysglycaemia than HIV-uninfected and ART-naïve HIV-infected participants, respectively.